AstraZeneca, Johnson & Johnson Resume Late-Stage COVID-19 Vaccine Trials

The drugmakers rejoin Pfizer and Moderna in phase 3 clinical trials

GARIN, ARGENTINA - AUGUST 13: Laboratory workers wearing PPE check a screen of a centrifuge machine at the production plant of mAbxience biotechnology company on August 13, 2020 in Garín, Argentina. The Argentina lab, property of Grupo Insud, will co-manufacture with Mexico the coronavirus vaccine created by Oxford University and Swedish-British pharmaceutical firm AstraZeneca.
Ricardo Ceppi/Getty Images

AstraZeneca and Johnson & Johnson announced Friday that they would resume their phase 3 clinical trials on COVID-19 vaccine candidates in the U.S, NBC News reports.

AstraZeneca’s trial was put on hold just days after it began in early September, following news of a British participant who developed a spinal cord injury after receiving the experimental vaccine. Johnson & Johnson’s trial was paused on Oct. 12 after an unspecified injury in one of its study participants.

Full NBC News coverage of the coronavirus outbreak

Coronavirus Pandemic

Full coverage of the COVID-19 outbreak and how it impacts you and our communities

Coronavirus in DC, Maryland, Virginia: What to Know on Jan. 24

DC Restaurants Welcome Customers Back Inside at 25% Capacity

The drugmakers rejoin Moderna and Pfizer in late-stage clinical trials in the U.S. Those companies have announced that they intend to submit applications for emergency use authorization in the second half of November, Mango said. On Thursday, Moderna said it had completed enrollment for its 30,000-person trial.

Read the full story at

Contact Us